Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
Top Page
Maze Therapeutics, Inc.
(NASDAQ:MAZE)
Select Model
Select Model
Rating:45Neutral
Price Target:
$27.00
▼(-3.88% Downside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by volatile fundamentals (sharp swing from profitable 2024 to zero-revenue, high-loss, cash-burning 2025) and weak technical momentum (below key moving averages with negative MACD). Offsetting factors include constructive corporate developments (positive Phase 2 data, milestone payment, and improved liquidity options), but valuation support is limited given losses and no dividend.
Positive Factors
Pivotal progression of MZE829
Clinically meaningful Phase 2 topline results and a stated plan to advance MZE829 to a pivotal stage materially de-risk the lead program. Progress to a registrational pathway increases long-term approval probability, partner interest, and potential durable revenue optionality if trials succeed.
Negative Factors
Volatile revenue and cash flow
The abrupt swing from positive operating results in 2024 to zero reported revenue and a large 2025 net loss signals an unstable commercial profile. Persistent volatility in revenue and operating cash flow undermines predictability, raising repeat financing risk and complicating multi-year planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal progression of MZE829
Clinically meaningful Phase 2 topline results and a stated plan to advance MZE829 to a pivotal stage materially de-risk the lead program. Progress to a registrational pathway increases long-term approval probability, partner interest, and potential durable revenue optionality if trials succeed.
Read all positive factors
Maze Therapeutics, Inc. (MAZE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.33B
Dividend YieldN/A
Average Volume (3M)1.00M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees125
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.65
Shares Outstanding49,708,656
10 Day Avg. Volume998,236
30 Day Avg. Volume1,000,385
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01K
Enterprise Value/Ebitda-8.61
Forecast
1Y Price Target
$64.50Price Target Upside129.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.93
Revenue Forecast (FY)$10.00M
Maze Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes M...
How the Company Makes Money
null...
Maze Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 167.50M | 0.00 | 0.00 |
| Gross Profit | -2.40M | 167.50M | 0.00 | 0.00 |
| EBITDA | -140.50M | 60.88M | -94.46M | -107.21M |
| Net Income | -131.12M | 52.23M | -100.42M | -114.94M |
Balance Sheet | ||||
| Total Assets | 397.13M | 240.54M | 71.50M | 149.96M |
| Cash, Cash Equivalents and Short-Term Investments | 341.92M | 196.81M | 29.16M | 99.92M |
| Total Debt | 23.31M | 26.63M | 49.62M | 32.05M |
| Total Liabilities | 42.16M | 43.64M | 61.45M | 48.51M |
| Stockholders Equity | 354.97M | 196.90M | 10.05M | 101.44M |
Cash Flow | ||||
| Free Cash Flow | -112.73M | 74.81M | -87.27M | -101.17M |
| Operating Cash Flow | -111.94M | 75.95M | -86.83M | -99.20M |
| Investing Cash Flow | -170.96M | -1.15M | -441.00K | -3.17M |
| Financing Cash Flow | 275.34M | 92.85M | 16.39M | 1.73M |
Maze Therapeutics, Inc. Risk Analysis
Maze Therapeutics, Inc. disclosed 83 risk factors in its most recent earnings report. Maze Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maze Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $572.32M | 5.14 | 58.50% | ― | 1647.67% | ― | |
54 Neutral | $1.07B | ― | -34.23% | ― | 522.13% | 62.68% | |
54 Neutral | $993.20M | -37.98 | -444.41% | ― | ― | -13.14% | |
53 Neutral | $2.02B | -101.81 | 1813.84% | ― | 196.42% | 53.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.60B | -14.96 | -57.48% | ― | 1137.19% | 70.51% | |
45 Neutral | $1.33B | -13.58 | -40.70% | ― | ― | ― |
* Healthcare Sector Average
MAZE
Maze Therapeutics, Inc.
26.69
18.19
214.00%
CRMD
Cormedix
7.24
0.11
1.54%
GERN
Geron
1.67
0.35
26.52%
KALV
KalVista Pharmaceuticals
19.39
7.44
62.26%
ANAB
AnaptysBio
70.10
52.24
292.50%
NUVB
Nuvation Bio
4.60
2.58
127.72%
Maze Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Maze Therapeutics adds Neil Kumar to board leadership
Positive
Mar 25, 2026
Maze Therapeutics reported fourth-quarter and full-year 2025 results on March 25, 2026, alongside positive Phase 2 HORIZON topline data for MZE829 showing clinically meaningful reductions in proteinuria in APOL1-mediated kidney disease, and confir...
Business Operations and StrategyPrivate Placements and Financing
Maze Therapeutics Secures New $200 Million Loan Facility
Positive
Feb 4, 2026
On February 4, 2026, Maze Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc. for a senior secured term loan facility of up to $200 million, with an initial $40 million tranche funded on the same date and net ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.